Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Age-related Macular Degeneration: early-phase trial registry
20 of 75 indexed Age-related Macular Degeneration trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #178 of 28,707 conditions by registered trial count.
75 US clinical trials · 20 currently recruiting · #178 of 28,707 conditions by registered trial count
Age-related Macular Degeneration: 75 US clinical trials tracked, 20 recruiting.
Age-related Macular Degeneration is the subject of 75 registered US clinical trials on ClinicalTrials.gov, 20 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 8 of these trials.
Enrollment posture brief
Registry condition age-related-macular-degeneration
OPEN 20 | RECR 27% | LATE 8 | EARLY 26 | RANK #178 | SPON 8
Volume-matched condition peers
Nearest open-share peer: AIDS (27% recruiting · 15 trials)
Age-related Macular Degeneration lists 20 open slots (27% of 75 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Age-related Macular Degeneration on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Age-related Macular Degeneration is recruiting below its size-band peers.
20 of 75 indexed trials (26.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Age-related Macular Degeneration trials is spread across many organizations.
National Eye Institute (NEI) accounts for 8 of 75 trials (10.7%). 53 distinct sponsors appear on at least one study for this condition label.
-
Typical Age-related Macular Degeneration enrolment sits around 79 participants.
Median target enrolment is 79 among the 75 trials that report a genuine target (sentinel values excluded). 42 of those (56%) plan for fewer than 100 participants.
-
Age-related Macular Degeneration splits between interventional and observational designs.
48 interventional and 27 observational studies make up this index (64% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
75 total, page 2 of 2
Genetic Load and Phenotype in Aggressive AMD
Sequenom
NCT01650948
Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)
i-Lumen Scientific
NCT05447650
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Iconic Therapeutics
NCT02358889
Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)
Carl Zeiss Meditec
NCT01272076
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
Guardion Health Sciences
NCT03946085
The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain
Virginia Polytechnic Institute and State University
NCT05542381
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
Bay Area Retina Associates
NCT00390208
A Study to Evaluate the Safety and Efficacy of RQC for AMD
Paul A Knepper, MD PhD
NCT05062486
Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study
National Eye Institute (NEI)
NCT01915238
30g vs 33g Needle for Intravitreal Injections
Wills Eye
NCT03038048
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
OcuTerra Therapeutics
NCT02914639
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Stealth BioTherapeutics
NCT02848313
The Focal Electro-Oculogram in Macular Disease
National Eye Institute (NEI)
NCT02225119
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
Mayo Clinic
NCT02951351
Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO
Optos
NCT01692938
Ocular Safety and Usability Study for FYB201 PFS
Formycon
NCT06708624
Ocular Safety and Usability Study for FYB203 PFS
Formycon
NCT06708637
Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
Potentia Pharmaceuticals
NCT00473928
Study Evaluating Retinal Health Monitoring System Visual Acuity Module.
Kubota Vision
NCT04169802
Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics
Vanderbilt University
NCT00831961
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals
NCT03954626
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD
Astellas Institute for Regenerative Medicine
NCT02463344
Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD
National Eye Institute (NEI)
NCT00766649
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
Ribomic USA
NCT03633084
Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
OnPoint Vision
NCT04984590
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 18 |
| Phase 2 | 8 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Age-related Macular Degeneration records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Age-related Macular Degeneration trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Age-related Macular Degeneration page
75 registered trials, 20 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 20 Age-related Macular Degeneration trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Age-related Macular Degeneration trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Age-related Macular Degeneration condition card totals 75 registered trials; most-linked intervention bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.